crofelemer
MYTESI (crofelemer) is (camp)-stimulated cystic fibrosis transmembrane conductance regulator (cftr) chloride ion (cl¯) channel, and the calcium-activated cl¯ channels (cacc) at the luminal membrane of enterocytes. First approved in 2012.
Drug data last refreshed 8m ago · AI intelligence enriched 2w ago
MYTESI (crofelemer) is an oral antidiarrheal small molecule approved in 2012 that acts as a chloride channel blocker, reducing fluid secretion in the gastrointestinal tract. It normalizes electrolyte and water balance by inhibiting cAMP-stimulated CFTR and calcium-activated chloride channels at the intestinal epithelium. The drug is indicated for non-infectious diarrhea in patients with HIV/AIDS on antiretroviral therapy.
Product is approaching loss of exclusivity with modest Part D utilization (~2,412 claims in 2023), suggesting a niche market with limited commercial team expansion.
(cAMP)-stimulated cystic fibrosis transmembrane conductance regulator (CFTR) chloride ion (Cl¯) channel, and the calcium-activated Cl¯ channels (CaCC) at the luminal membrane of enterocytes. The CFTR Cl¯ channel and CaCC regulate Cl¯ and fluid secretion by intestinal epithelial cells. Crofelemer…
Antidiarrheal
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients
Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea
Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea
A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moMYTESI offers limited career opportunity signal given zero linked job postings and approaching loss of exclusivity. Working on this product would primarily involve commercial execution in a niche, stable market rather than growth-stage innovation or expansion work.